Sign inJoin waitlistJoin the waitlist

Keri Maher

Physician · Virginia Commonwealth University School of Medicine

Credentials: · · · · ·

History

Virginia Commonwealth University School of Medicine
2020–Present

Fred Hutchinson Cancer Center
2014–2017
Hematology and Medical Oncology
University of Arizona College of Medicine-Tucson
2011–2014
Internal Medicine
University of Arizona College of Medicine-Tucson
2011–2014
Western University of Health Sciences
2007–2011
California State University
2007
California State University
2003

Research

Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives
Review · Blood Reviews · 2023 · 35 citations
Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia
eJHaem · 2023 · Last of 14 authors · 21 citations
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome
Cancer Chemotherapy and Pharmacology · 2025 · First of 10 authors · Corresponding · 18 citations

SG
Steven Grant
10 papers
Ian Bouligny
9 papers · 9 as a fellow
GM
Graeme Murray
6 papers · 6 as a resident
Juhi Gor
5 papers · 5 as a resident
TH
Thuy Ho
5 papers · 4 as a fellow
JB
Joshua Boron
4 papers · 4 as a resident
MD
Michael Doyel
4 papers
Tilak Patel
4 papers · 4 as a resident
VT
Valerie Tran
4 papers · 4 as a resident
YA
Yanal Alnimer
4 papers
Yi Hang
4 papers
Andrew Yeager
2 papers

Grants

Driving Transformation in NCI-Sponsored Clinical Trials Through Education, Leadership, and Community Partnership: An NCI-R50 Clinical-Scientist Award
National Cancer Institute · R50
Contact PI · $129.2K · Virginia Commonwealth University
2026–2031
Massey Cancer Center - Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $71.3K · Virginia Commonwealth University
1995–2028

Clinical trials

Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN
Principal investigator · Recruiting · Phase 2
Virginia Commonwealth University
2026–2033
Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
Principal investigator · Recruiting · Phase 1
Virginia Commonwealth University
2026–2030
Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
Principal investigator · Recruiting · Phase 4
Virginia Commonwealth University
2024–2029
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Principal investigator · Terminated · Phase 1
National Cancer Institute (NCI)
2019–2025